Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
152.80    -0.20 (-0.13%)
Bid:
153.20
Ask:
153.60
Spread: 0.40 (0.261%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Trading Update

21 Jan 2026 07:00

RNS Number : 6780P
Elementis PLC
21 January 2026
 

21 January 2026

 

 

Elementis plc

Trading Update

 

Resilient performance in challenging markets

Trading marginally ahead of full year expectations

 

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues its scheduled trading update for the three months and year ended 31 December 2025.

Elementis will publish its results for the financial year to 31 December 2025 on 5 March 2026.

Business performance

The Group has delivered a resilient performance with Revenues1 expected to be in line with market consensus2, despite the ongoing challenging market conditions.

Full year Group Adjusted operating profit1 is expected to be marginally ahead of market consensus2, with Adjusted operating margins1 ahead of last year. The improved margin performance has been driven by the benefits of our Elevate Elementis strategy and the positive changes being implemented across the Group, as we look to build on our strong foundations. These include: the simplification of our operational structure to enhance efficiency and agility, the bolt-on acquisition of UK based Alchemy Ingredients Limited ("Alchemy") in November 2025, as well as the ongoing delivery of our previously announced cost savings targets.

Balance sheet strength

The Group continues to generate positive free cash flow that gives us balance sheet strength and future capital allocation optionality.

Net debt pre IFRS 16 basis at the end of the financial year 2025 is expected to be c.$185m. This reflects several one-off cash payments during the year including: the successful completion of the Group's first share buyback programme for a total consideration of £40m (c.$54m), the previously announced disposal of the disused manufacturing site and associated environmental liabilities at Eaglescliffe, UK, for $11m, and the acquisition of Alchemy for $22m.

Chair succession

Further to the announcement on 29 October 2025, the Chair succession process continues to progress and an update will be provided in due course.

 

 

Enquiries

Investors: Zeeshan Maqbool, Elementis plc Tel: +44 (0) 7553 340380

Press: Martin Robinson/Giles Kernick, Teneo Tel: +44 (0) 20 7353 4200

 

 

 

 

 

 Notes:

1. Continuing operations basis.

2. Based on company compiled consensus dated 20 January 2026, the mean revenue and adjusted operating profit for the year ended 31 December 2025 are $600m and $125m respectively.

 

 

About Elementis

Elementis is a global specialty chemicals company listed on the London Stock Exchange. The Group employs c.1,000 across 20 global locations. As recognised innovation leaders with deep expertise in rheology (the science of flow), and formulation solutions, we develop distinctive solutions and products to improve performance, achieve smoother production, and enhance sustainability credentials for customers across a range of industries. The Group also owns and operates one of the largest known commercial high-grade hectorite mines in the world. Hectorite is a special, high-purity clay mineral rich in magnesium and lithium, known for its ability to control viscosity, stabilise formulations, and deliver smooth, consistent textures that make it ideal for clean-label, high-performance formulations. 

Elementis is composed of two focused, high-margin businesses: Personal Care and Coatings. The Personal Care business manufactures natural and synthetic rheology modifiers to deliver premium product performance for personal care applications in skin care and cosmetics, as well as active ingredients for antiperspirants. Within Coatings, Elementis develops and manufactures rheology modifiers and premium performance additives for decorative and industrial paints and coatings. The Coatings business also includes our Energy and Adhesives, Sealants and Construction additives businesses.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTZZGZMLGLGVZM
Date   Source Headline
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights
31st Jan 20233:04 pmRNSSale of Chromium business
19th Jan 20237:00 amRNSTrading Update
3rd Jan 20239:47 amRNSTotal Voting Rights
8th Dec 20222:10 pmRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSSale of Chromium business
23rd Nov 20223:54 pmRNSHolding(s) in Company
16th Nov 20221:43 pmRNSHolding(s) in Company
10th Nov 20229:40 amRNSHolding(s) in Company
10th Nov 20227:00 amRNSDirectorate Change
1st Nov 20229:48 amRNSTotal Voting Rights
31st Oct 20223:23 pmRNSHolding(s) in Company
26th Oct 20227:00 amRNSQ3 Trading Update
18th Oct 20223:13 pmRNSHolding(s) in Company
3rd Oct 20229:39 amRNSTotal Voting Rights
29th Sep 202212:45 pmRNSDirector/PDMR Shareholding
29th Sep 202210:12 amRNSDirector/PDMR Shareholding
22nd Sep 202211:17 amRNSDirector/PDMR Shareholding
21st Sep 20224:58 pmRNSDirector/PDMR Shareholding
21st Sep 20223:48 pmRNSDirector/PDMR Shareholding
6th Sep 202212:52 pmRNSDirector Declaration
5th Sep 20224:14 pmRNSAdditional Listing
1st Sep 202212:39 pmRNSHolding(s) in Company
1st Sep 20229:15 amRNSBlock listing Interim Review
1st Sep 20229:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.